Understanding GLP-1 Receptor Agonists
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications that have revolutionized weight management. Originally designed for type 2 diabetes, they have shown remarkable efficacy for weight loss in clinical trials.
Semaglutide vs. Tirzepatide: The Data
Semaglutide
(Brand names: Ozempic®, Wegovy®)
- Mechanism: GLP-1 agonist only.
- Clinical Trial: STEP 1 (68 weeks).
- Average Loss: ~14.9% of body weight.
Tirzepatide
(Brand names: Mounjaro®, Zepbound®)
- Mechanism: Dual GLP-1 and GIP agonist.
- Clinical Trial: SURMOUNT-1 (72 weeks).
- Average Loss: ~20.9% of body weight (at highest dose).
What does 15-20% weight loss look like?
Numbers on a scale are one thing, but seeing the physical change is another. A 15-20% reduction in body weight significantly alters body composition, face shape, and overall silhouette.
Visualize Your "After" Photo
Our AI models are trained to simulate realistic weight loss effects on the face and body. Upload a photo to see exactly how the medication's projected results would look on you.
Disclaimer: This tool provides estimates based on average results from clinical trials (STEP 1 and SURMOUNT-1). Individual results vary based on dosage, lifestyle (diet/exercise), adherence, and biological factors. Consult a healthcare professional for medical advice.